Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease

Xenobiotica

Volumn 29, Issue 7, 1999, Pages 747-762

  Azuma, R ^d   Komuro, M ^d   Korsch, B H ^a   Andre, J C ^a,e   Onnagawa, O ^b   Black, S R ^c   Mathews, J M ^c  

^a Ricerca Inc   (United States)

^b TORAY RESEARCH CENTER INC   (Japan)

^c RTI INTERNATIONAL   (United States)

^d MPI ^*

^e MPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; CYTOCHROME P450;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BILE; BIOTRANSFORMATION; CONTROLLED STUDY; DEMETHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; FECES; GLUCURONIDATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; URINARY EXCRETION;

ALZHEIMER DISEASE; ANIMALS; AREA UNDER CURVE; BENZYLIDENE COMPOUNDS; BILE; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; FECES; HUMANS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NICOTINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; URINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032798625     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238362     Document Type: Article

References (21)

1. AZUMA, R., MINAMI, Y. and SATOH, T., 1996, Simultaneous determination of GTS-21 and its metabolite in rat plasma by high-performance liquid chromatography using solid-phase extraction. Journal of Chromatography B: Biomedical applications, 686, 229-234.
2. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of CYP3A and CYP2C9. Xenobiotica, 25, 261-270.
3. 13C assignments from sensitivity-enhanced detection of heteronuclcar multiple-bond connectivity by 2D multiple quantum NMR. Journal of American Chemical Society, 108, 2093-2094.
4. CHANG, T. K., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437-442.
5. CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517-526.
6. 125I-α-bungarotoxin receptor subtypes. Molecular Pharmacology, 47, 164-171.
7. FLOCKHART, D. A., 1995, Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clinical Pharmacokinetics, 29 (Suppl. 1), 45-52.
8. HUNTER, B. E., DE FIBRE, C, M., PAPKE, R. L., KEM, W. R. and MAYER, E. M., 1994, A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neuroscience Letters, 168, 130-134.
9. KITAGAWA, H., MORIYAMA, A., TAKENOUCHI, T., WESNES, K., KRAMER, W. and CLODY, D. E., 1998, Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers. Neurobiology of Aging, 19 (Suppl. 2), S182.
10. KO, J. W., SUKHOVA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853-862.
11. MACHINIST, J. M., MAYER, M. D., SHET, M. S., FERRERO, J. L. and RODRIGUES, A. D., 1995, Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metabolism and Disposition, 23, 1163-1174.
12. MAHNIR, V., LIN, B., PROKAI-TATRAI, K. and KEM, W. R., 1998, Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. Biopharmaceutics and Drug Disposition, 19, 147-151.
13. MATHEWS, J. M., ETHERIDGE, A. S., RAYMER, J. H., BLACK, S. R., PULLIAM, D. W. JR and BUCHER, J. R., 1998, Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1,2-dichloroethylene. Chemical Research in Toxicology, 11, 778-785.
14. MEYER, E. M, KING, M. A. and MEYERS, C., 1998, Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Research, 786, 252-254.
15. NANRI, M., YAMAMOTO, J., MIYAKE, H. and WATANABE, H., 1998, Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Japanese Journal of Pharmacology, 76, 23-29.
16. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
17. SHAH, V. P., MIDHA, K. K., DIGHE, S., MCGILVERAY, I. J., SKELLY, J. P., YACOBI, A., LAYLOFF, T., VISWANATHAN, C. T., COOK, C. E., McDOWALL, R. D., PITTMAN, K. A. and SPECTOR, S., 1992, Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. Journal of Pharmaceutical Sciences, 81, 309-312.
18. SHIMOHAMA, S., GREENWALD, D. L., SHAFRON, D. H., AKAIKA, A., MAEDA, T., KANEKO, S., KIMURA, J., SIMPKINS, C. E., DAY, A. L. and MEYER, E. M., 1998, Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Research, 779, 359-363.
19. SUMMERS, K. L., KEM, W. R. and GIACOBINI, E., 1997, Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Japanese Journal of Pharmacology, 74, 139-146.
20. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TURKEY, R. H, QUATTROCHI, L, C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
21. ZOLTEWICZ, J. A., PROKAI-TATRAI, K., BLOOM, L. B. and KEM, W. R., 1993, Long range transmission of polar effects in cholinergic 3-arylideneanabaseines. conformations calculated by molecular modelling. Heterocycles, 35, 171-179.